



Online article and related content
current as of November 25, 2009.

Association of Funding and Conclusions in Randomized Drug Trials: A Reflection of Treatment Effect or Adverse Events?

Bodil Als-Nielsen; Wendong Chen; Christian Gluud; et al.

JAMA. 2003;290(7):921-928 (doi:10.1001/jama.290.7.921)

<http://jama.ama-assn.org/cgi/content/full/290/7/921>

Correction

[Contact me if this article is corrected.](#)

Citations

This article has been cited 185 times.
[Contact me when this article is cited.](#)

Topic collections

Medical Practice; Conflict of Interest; Statistics and Research Methods;
Randomized Controlled Trial; Drug Therapy; Adverse Effects; Drug Therapy, Other

[Contact me when new articles are published in these topic areas.](#)

Related Letters

Results of Clinical Trials Sponsored by For-Profit vs Nonprofit Entities
[Robert H. Palmer. *JAMA*. 2003;290\(23\):3070.](#)
[Jonathan B. Rosefsky. *JAMA*. 2003;290\(23\):3070.](#)
[Stig Waldorff. *JAMA*. 2003;290\(23\):3071.](#)

Subscribe

<http://jama.com/subscribe>

Permissions

permissions@ama-assn.org

<http://pubs.ama-assn.org/misc/permissions.dtl>

Email Alerts

<http://jamaarchives.com/alerts>

Reprints/E-prints

reprints@ama-assn.org

Association of Funding and Conclusions in Randomized Drug Trials

A Reflection of Treatment Effect or Adverse Events?

Bodil Als-Nielsen, MD

Wendong Chen, MD

Christian Gluud, MD, DMSc

Lise L. Kjaergard, MD

EMPIRICAL EVIDENCE SHOWS THAT conclusions in randomized trials are more positive toward experimental interventions if funded by for-profit organizations.¹⁻⁷ Three studies found this association in randomized trials published in high-impact journals.¹⁻³ Two studies reached similar results in randomized trials on arthritis⁴ and myeloma.⁵ Two recent systematic reviews^{6,7} highlight the external validity of these findings. It is not known whether this association reflects the quantitative trial results.⁸ More positive conclusions in trials funded by for-profit organizations could reflect either more beneficial treatment effects or less frequent occurrence of adverse events. None of the previous studies¹⁻⁷ assessed these aspects. Furthermore, previous studies included relatively heterogeneous trial cohorts. This case mix could confound the findings. It is possible that the association simply reflects that trials funded by for-profit organizations assess the most effective interventions.

The influence of methodological quality, type of control intervention, sample size, and disease area also could be important. These variables were assessed only in 1 study but did not appear to explain the association between funding and conclusions.³

Context Previous studies indicate that industry-sponsored trials tend to draw pro-industry conclusions.

Objective To explore whether the association between funding and conclusions in randomized drug trials reflects treatment effects or adverse events.

Design Observational study of 370 randomized drug trials included in meta-analyses from Cochrane reviews selected from the Cochrane Library, May 2001. From a random sample of 167 Cochrane reviews, 25 contained eligible meta-analyses (assessed a binary outcome; pooled at least 5 full-paper trials of which at least 1 reported adequate and 1 reported inadequate allocation concealment). The primary binary outcome from each meta-analysis was considered the primary outcome for all trials included in each meta-analysis. The association between funding and conclusions was analyzed by logistic regression with adjustment for treatment effect, adverse events, and additional confounding factors (methodological quality, control intervention, sample size, publication year, and place of publication).

Main Outcome Measure Conclusions in trials, classified into whether the experimental drug was recommended as the treatment of choice or not.

Results The experimental drug was recommended as treatment of choice in 16% of trials funded by nonprofit organizations, 30% of trials not reporting funding, 35% of trials funded by both nonprofit and for-profit organizations, and 51% of trials funded by for-profit organizations ($P < .001$; χ^2 test). Logistic regression analyses indicated that funding, treatment effect, and double blinding were the only significant predictors of conclusions. Adjusted analyses showed that trials funded by for-profit organizations were significantly more likely to recommend the experimental drug as treatment of choice (odds ratio, 5.3; 95% confidence interval, 2.0-14.4) compared with trials funded by nonprofit organizations. This association did not appear to reflect treatment effect or adverse events.

Conclusions Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results. Readers should carefully evaluate whether conclusions in randomized trials are supported by data.

JAMA. 2003;290:921-928

www.jama.com

Moreover, financial interests may influence the decision to submit trials with positive results to high-impact journals.

We assessed whether an association between funding and conclusions in randomized drug trials reflects the magnitude of the treatment effect or occurrence of adverse events. Secondary objectives were to explore the

impact of methodological quality, type of control intervention, size of the trial, year of publication, or publica-

Author Affiliations: The Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark.

Corresponding Author and Reprints: Bodil Als-Nielsen, MD, The Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, H:S Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark (e-mail: bodil.a@ctu.rh.dk).

Box. Scale Used to Grade Conclusions in Trials**6 Points**

Experimental intervention highly preferred and should now be considered the standard intervention in all patients, or similar

5 Points

Experimental intervention preferred to control, but further trials still indicated, experimental may be more costly, or similar

4 Points

Experimental and control intervention about equal, but the experimental cheaper, easier to administer, or similar minor advantage

3 Points

Experimental and control intervention about equal, but the control may be cheaper, easier to administer, or similar minor advantage

2 Points

Control intervention preferred to experimental intervention, but experimental intervention might be promising under some circumstances, or similar

1 Point

Control intervention highly preferred and should now be considered the standard intervention in all patients, or similar

tion in high-impact journals on this association.

METHODS

We selected all randomized trials included in eligible meta-analyses from a random sample of Cochrane reviews obtained in May 2001 and extracted data on conclusions, funding, treatment effect, adverse events, and additional confounding factors. The primary outcome for each trial was selected according to the meta-analysis including the trial. We analyzed whether an association between funding and conclusions reflected treatment effects or adverse events.

Selection of Meta-analyses

We selected meta-analyses of randomized trials because within each meta-analysis, trials assessed comparable treatments for specific diseases. This allowed us to adjust for disease areas and type of experimental and control intervention. Meta-analyses of binary outcomes were selected to adjust our analyses for the treatment effect estimated by an odds ratio (OR). To reduce the number of empty cells in our analyses, the

meta-analyses had to include at least 5 full-paper trials. To examine the impact of trial quality, the meta-analyses had to include at least 1 trial with and 1 trial without adequate allocation concealment.⁹⁻¹¹ Our inclusion criteria were adopted from previous methodological studies.^{9,11,12} We included all full-paper trials that were contained in eligible meta-analyses.

Based on a pilot study of 100 systematic reviews, we estimated that about 25% of all reviews published in the Cochrane Library would contain an eligible meta-analysis. We also estimated that we had to include about 40 reviews to obtain a sample of about 500 trials. Previous studies^{1-3,5} have indicated that this number would provide an acceptable risk of type II error. The number of systematic reviews in the Cochrane Library 2001, Issue 2 was 1081.¹³ To obtain about 40 reviews, we used a computer-generated list of random numbers in blocks of 26 and randomly selected 4 trials from each block. This resulted in 167 systematic reviews, which were screened by one author (B.A.-N.) for eligible meta-analyses.

Selection of Primary Outcome

Two of the authors (B.A.-N., L.L.K.) independently selected the primary binary outcome for each included meta-analysis. The primary binary outcome from each meta-analysis was considered the primary outcome for all trials included in each meta-analysis. If it was not explicitly reported or several primary outcomes were listed, we chose the most clinically relevant outcome, assessed by the largest number of trials.

Data Extraction and Definitions

All data were extracted from the original trial reports. We defined conclusions as the interpretation of the extent to which the overall trial results favored the experimental over the control intervention. We graded conclusions according to the phrasing in the abstract and the summarized conclusion on a scale of 1 to 6 points (BOX).¹⁴ The higher the score, the more positive the conclusion toward the experimental intervention. Because the score did not conform to a normal distribution, we divided conclusions into whether the experimental drug was recommended as the treatment of choice without disclaimers (6 points) or not (1-5 points).

We extracted the sources of funding from the text, statements of sources of support, authors' affiliations, and acknowledgments. Funding sources were classified as nonprofit organizations, not reported, both nonprofit and for-profit organizations, or for-profit organizations. For-profit organizations were defined as companies that might acquire financial gain or loss depending on the outcome of the trial. Funding included provision of grants, study materials (drug, placebo, assay kits, or similar materials), or manpower (authorship, statistical analysis, or other assistance). For the primary binary outcome measure, we extracted the number of outcomes and participants in the experimental and control groups.

We classified the occurrence of adverse events as (1) no significant difference between experimental and con-

trol group, (2) significantly more frequent in the control group, (3) significantly more frequent in the experimental group, or (4) not reported.

We assessed methodological quality from the original trial reports and any additional information provided in the Cochrane review. We assessed the following 3 components^{10,11}: generation of the allocation sequence (classified as adequate if based on a table of random numbers, computer-generated, or similar), allocation concealment (classified as adequate if based on central randomization, identical coded drug boxes, sealed envelopes, or similar), and double blinding (classified as adequate if the trial was described as double blind). We extracted the type of control intervention (placebo/no intervention or active intervention), the number of patients randomized, and whether a preset sample size was estimated and reached. We registered the meta-analysis in which the trial was included, the year of publication, and whether the trial was published in a high-impact journal (impact factor ≥ 6).¹⁻³

Two authors (B.A.-N., W.C.) independently extracted data from each trial in an unblinded manner. Consensus was achieved before data entry. A third author (C.G.) arbitrated disagreements. A fourth author (L.L.K.), who was blinded with regard to funding, extracted conclusions in a random sample of 60 trials. The intraclass correlation coefficient between blinded and unblinded assessment of conclusions was 0.93 (95% confidence interval [CI], 0.89-0.96).

Statistical Analysis

For each trial, we estimated the OR of an unfavorable outcome (eg, mortality). The SE of the logarithm of the OR was calculated as a measure of uncertainty.¹⁵ We calculated a *z* score (log OR/SE to log OR) as a measure of treatment effect.¹⁵ The *z* score combines the magnitude of the point estimate (log OR) with the level of uncertainty (SE).

We used the Kruskal-Wallis test for testing the overall null hypothesis of no association between funding and conclusions assessed on the continuous

scale. We used a cutoff value between 5 and 6 points to divide trials into whether the conclusions recommended the experimental drug as the treatment of choice or not. We used logistic regression to assess the association between funding and conclusions while adjusting for treatment effect, adverse events, and other potentially confounding trial variables (methodological quality, sample size, whether preset sample size was estimated and reached, meta-analysis, year of publication, and journal impact factor). The logistic regression model was fit using conclusions as the dependent variable and including trial variables in a forward stepwise procedure. Meta-analysis was kept in the model irrespective of statistical significance to adjust for the disease area and type of drug and control intervention. All other variables were excluded if $P > .05$. The appropriateness of the logistic regression models was confirmed by the Hosmer-Lemeshow test.¹⁶ All *P* values were 2-tailed and significance was defined as $P < .05$. Analyses were performed in SPSS version 11.0 for Windows (SPSS Inc, Chicago, Ill).

RESULTS

Identification of Eligible Trials

From our random sample of 167 Cochrane reviews, we excluded 126 that included fewer than 5 full-paper randomized trials in a meta-analysis ($n = 105$), included only trials with adequate ($n = 6$) or inadequate allocation concealment ($n = 13$), or did not assess a binary outcome ($n = 2$). The remaining 41 reviews contained meta-analyses, which included 523 trials, that met our inclusion criteria. Sixteen of these reviews, which included 153 trials, assessed nonpharmacological interventions. Initial analyses revealed that only 4 (3%) of these trials were funded by for-profit organizations. We therefore limited our analyses to the 370 drug trials (references available on request from the authors) from 25 reviews.¹⁷⁻⁴¹

Description of Included Trials

In most trials, conclusions favored the experimental drug (median score [in-

terquartile range], 5 [4-6]). In 36% of trials ($n = 135$), the experimental drug was recommended as the treatment of choice (6 points).

Eighteen percent of trials ($n = 67$) were funded by nonprofit organizations and in 29% ($n = 106$) funding was not reported. Fourteen percent of trials ($n = 51$) were funded by both nonprofit and for-profit organizations and 39% ($n = 146$) by for-profit organizations alone. The treatment effect assessed by the mean (SD) *z* score was -1.39 (1.90) (range, -10.99 to 5.45). In 50% of the trials ($n = 185$), the occurrence of adverse events did not differ significantly between the intervention groups, and in 5% ($n = 20$) the occurrence was significantly higher in the control than that in the experimental group. In 16% of trials ($n = 60$), the occurrence of adverse events was significantly higher in the experimental group, and in 28% ($n = 105$) adverse events were not reported.

Adequate generation of the allocation sequence was reported in 28% of trials ($n = 105$), adequate allocation concealment in 22% ($n = 82$), and 63% ($n = 234$) were double blind. In 76% of trials ($n = 283$), the control intervention was placebo or no intervention. The median number of patients randomized was 98 (range, 10-82892). Preset sample size was estimated and reached in 21% of trials ($n = 76$).

The disease areas were intensive care ($n = 85$), smoking cessation ($n = 78$), respiratory diseases ($n = 54$), gynecology/obstetrics ($n = 48$), gastroenterology ($n = 33$), neurology ($n = 26$), psychiatry ($n = 13$), infectious diseases ($n = 12$), rheumatology ($n = 9$), nephrology ($n = 6$), and dermatology ($n = 6$). The primary outcome measures were smoking cessation ($n = 78$), mortality ($n = 64$), blood transfusion ($n = 61$), withdrawals ($n = 33$), dysphagia ($n = 23$), endometritis ($n = 20$), parasitemia ($n = 17$), depression ($n = 13$), admission to hospital ($n = 11$), bronchiolitis ($n = 8$), neurologic deficit ($n = 8$), cesarean delivery ($n = 7$), warts ($n = 6$), cytomegalovirus disease ($n = 6$), pregnancy ($n = 5$), bacterial vaginosis ($n = 5$), and asthma ($n = 5$).

The year of publication ranged from 1971 to 2000 with 1990 (5.6 years) as the mean (SD) publication year. Eighteen percent of trials (n=65) were published in high-impact journals.

Characteristics of Trials Stratified by Funding

The conclusions in trials stratified by funding are shown in TABLE 1. Conclusions were significantly more favorable toward experimental drugs in trials funded by for-profit organizations compared with those of trials funded by other sources ($P<.001$, Kruskal-Wallis test). The proportion of trials in which conclusions recommended the experimental drug as the treatment of choice (6 points) was significantly

higher among trials with for-profit funding compared with that of other trials ($P<.001$, χ^2 test).

The distributions of the potential confounding variables stratified by funding are shown in TABLE 2. Funding by for-profit organizations alone or by for-profit and nonprofit organizations was associated with more complete reporting of adverse events, more adverse events in the experimental group, more frequent report of adequate allocation concealment and double blinding, and more frequent use of placebo or no treatment as control intervention. Funding by both nonprofit and for-profit organizations also was associated with a larger sample size and publication in high-impact journals. No

significant difference was observed between the groups regarding the treatment effect, adequate generation of the allocation sequence, or whether a pre-set sample size had been estimated and reached.

Funding and Conclusions Adjusted for Confounders

The logistic regression analyses showed that funding, treatment effect, and double blinding were significantly associated with conclusions (TABLE 3). None of the remaining variables were associated significantly with conclusions. After adjusting for the treatment effect and double blinding, conclusions were significantly more likely to recommend the experimental drug as treatment of choice in trials funded by for-profit organizations alone compared with trials funded by nonprofit organizations (OR, 5.3; 95% CI, 2.0-14.4). Compared with trials funded by nonprofit organizations, conclusions were not significantly different in trials not reporting funding or trials funded by both nonprofit and for-profit organizations. The likelihood of recommending the experimental drug as the treatment of choice decreased

Table 1. Relation Between Funding Source and Conclusions in 370 Randomized Drug Trials*

Funding	No. of Trials	Median Score (IQR)†	No. (%) of Trials Scoring 6 Points‡
Nonprofit organizations	67	4 (3-5)	11 (16.4)
Not reported	106	5 (3-6)	32 (30.1)
Nonprofit and for-profit organizations	51	5 (4-6)	18 (35.2)
For-profit organizations	146	6 (5-6)	74 (50.6)
Total	370	5 (4-6)	135 (36.4)

Abbreviation: IQR, interquartile range.

*Conclusions in trials were assessed by a 1-6 point scale. If the conclusions recommended the experimental drug as the treatment of choice without disclaimers, 6 points was assigned, and if not, 1-5 points was assigned.

† $P<.001$, using Kruskal-Wallis test (medians) or χ^2 test (proportions).

Table 2. Characteristics of Trials According to Funding

Characteristic	Nonprofit (n = 67)	Not Reported (n = 106)	Nonprofit and For-Profit (n = 51)	For-Profit (n = 146)
Treatment effect, z score, mean (SD)	-1.20 (2.56)	-1.20 (1.51)	-1.77 (1.86)	-1.48 (1.80)
Occurrence of adverse events, No. (%)*				
No significant difference	21 (31.3)	54 (50.9)	17 (33.3)	93 (63.6)
More in control group	8 (11.9)	5 (4.7)	5 (9.8)	2 (1.3)
More in experimental group	3 (4.5)	10 (9.4)	14 (27.4)	33 (22.6)
Not reported	35 (52.3)	37 (34.9)	15 (29.4)	18 (12.3)
Adequate methodological quality, No. (%)				
Allocation sequence generation	20 (29.8)	23 (21.6)	19 (37.3)	43 (29.4)
Allocation concealment†	13 (19.4)	14 (13.3)	17 (33.3)	38 (26.0)
Double blinding*	32 (47.7)	52 (49.8)	42 (82.4)	108 (73.4)
Placebo or no control intervention‡	44 (65.7)	76 (71.6)	45 (88.2)	118 (80.8)
Sample size				
Median (range)*	120 (10-14 046)	55 (12-497)	178 (13-82 892)	110 (11-3575)
Preset sample size reached, No. (%)	10 (14.9)	16 (15.0)	13 (25.5)	37 (25.3)
Publication year, mean (SD)	1989 (6)	1990 (5)	1990 (6)	1991 (5)
Journal impact factor ≥ 6 , No. (%)†	12 (17.9)	11 (10.4)	16 (31.3)	26 (17.9)

* $P<.001$, using Kruskal-Wallis test (medians) or χ^2 test (proportions).

† $P = .02$, using χ^2 test.

‡ $P = .001$, using χ^2 test.

with decreasing treatment effect (OR, 0.6; 95% CI, 0.5-0.7) and increased with adequate double blinding (OR, 2.9; 95% CI 1.4-6.0) (Table 3).

COMMENT

In randomized drug trials from a randomly selected sample of reviews published in the Cochrane Library,¹³ we found that conclusions of trials were significantly more likely to recommend the experimental drug as the treatment of choice if trials were funded by for-profit organizations. This result is in accordance with previous studies.¹⁻⁷ The present study adds to previous evidence by showing that this association does not reflect the quantitative trial results; neither the magnitude of the treatment effect nor the occurrence of adverse events could explain the association.

We selected meta-analyses from a random sample of Cochrane reviews because the Cochrane Collaboration is a nonprofit organization that aims to minimize the influence of financial and other competing interests. Furthermore, Cochrane reviews appear to be of higher quality and are less prone to bias than reviews published in traditional medical journals.⁴²⁻⁴⁴ We excluded a high (75%) but expected number of the randomly selected reviews because they did not contain a meta-analysis that fulfilled our inclusion criteria. Furthermore, only 3% of the non-pharmacological trials in our original sample were funded by for-profit organizations. Because of the low frequency of for-profit funding, these trials would not contribute valuable information, but rather introduce noise into the analyses.⁴⁵ Therefore, these trials also were excluded. Considering that more than 360 000 randomized clinical trials have been published,⁴⁶ our results are based on a small sample. These factors may reduce the external validity of our study. However, our sample was obtained randomly from the Cochrane Library, which covers all medical areas.¹³ The included trials covered a variety of medical areas, drugs, publication years, and journals. This variabil-

Table 3. Estimated Effect of Funding, Treatment Effect, and Double Blinding on Conclusions

Characteristic	Odds Ratio (95% Confidence Interval)	P Value
Funding		.005
Nonprofit organizations	1.0	
Not reported	2.4 (0.9-6.8)	.10
Nonprofit and for-profit organization	2.6 (0.9-7.9)	.09
For-profit organizations	5.3 (2.0-14.4)	.001
Treatment effect (z score)*	0.6 (0.5-0.7)	<.001
Double blinding	2.9 (1.4-6.0)	.004

*The likelihood of recommending the experimental drug as the treatment of choice decreased with higher z scores (the higher the score the smaller the benefit of the experimental drug).

ity supports the external validity of our findings.

Within each meta-analysis, trials addressed the same clinical question, compared the same treatments, and provided data on the same outcome measure. We therefore were able to adjust our analyses for both disease areas and type of experimental and control treatments. Therefore, the clinical importance of the treatment corresponds to the magnitude of the treatment effect. Together the point estimate (OR) and the level of uncertainty (SE) provide information about the treatment effect. We used a z score to capture these 2 aspects in 1 variable. We found similar results when including the OR and the SE of the treatment effect separately in the logistic regression model (data not shown). The magnitude of the treatment effect did not explain the association between funding and conclusions.

To estimate the treatment effect, we selected the primary binary outcome specified in the meta-analysis including the trial. We did this to obtain clinically important and homogeneous data. Many randomized trial reports do not specify the primary outcome measures,⁴⁷ use surrogate outcomes,⁴⁸⁻⁵¹ or use multiple primary outcomes.⁵² Cochrane reviews are based on prespecified, peer-reviewed, and published protocols in which the outcome measures most clinically relevant to patients are selected.⁵³ Accordingly, the selection of the primary outcome measure in Cochrane reviews aims to be unbiased and not data driven.⁵²

The favoring of experimental drugs in trials funded by for-profit organiza-

tions did not appear to reflect the occurrence of adverse events. Compared with trials funded by nonprofit organizations, trials funded by for-profit organizations reported a significantly higher number of adverse events in the experimental arm. This might reflect differences in the quality of reporting. Possibly, drug companies are more focused on reporting of adverse events because of use of Good Clinical Practice guidelines.⁵⁴

We assessed the effect of several potential confounders. These were selected according to previous evidence and theoretical considerations. Several of the confounders had some overlap (eg, the treatment effect and the use of inactive control, double blinding and the use of placebo as control intervention). However, this overlap only increased the SEs of the logistic regression model but did not invalidate the model. Our results indicated that the methodological quality, type of control intervention, sample size, whether a preset sample size had been estimated and reached, year of publication, or publication in high-impact journals did not explain the association between funding and conclusions.

Trials funded by for-profit organizations had better methodological quality than trials funded by nonprofit organizations regarding allocation concealment and double blinding. This finding is in accordance with previous studies.^{57,55} We are aware that discrepancies might occur between report and conduct of trials.⁵⁶ The Cochrane Collaboration recommends that reviewers correspond with the primary inves-

tigators of trials and companies to obtain information about central methodological aspects.⁵³ We based our assessment of quality on both the trial reports and any additional information provided in the Cochrane reviews.¹⁷⁻⁴¹

We assessed the reported conclusions using a scale developed by Gilbert et al.¹⁴ The lack of validation of this scale may be criticized.²⁰ However, the scale has been used in 3 studies,^{3,5,57} and we found that it had high face and content validity as well as high reliability. One study analyzed the reported conclusions on the continuous scale.³ Other studies divided the reported conclusions into "positive" or "negative."^{1,2,4,5} In the present study, only 20% of the trials scored 1 to 3 points. This skewed distribution of data supported the use of a cutoff value between 5 and 6 points. This allowed us to explore whether conclusions were more likely to recommend the experimental drug as the treatment of choice without disclaimers. Such conclusions must have a considerable impact on clinical decision making. Sensitivity analyses revealed that selecting another cutoff (eg, between 4 and 5 points) gave similar results. This increases the robustness of the evidence and supports the existence of an association between funding and conclusions.¹⁻⁷

A potential weakness of the present study is that the reported conclusions were assessed unblinded with regard to the source of funding. However, we found high interobserver agreement between blinded and unblinded assessment. This concurs with previous findings^{3,58} and suggests that blinding would not significantly change our conclusions.

Sponsor involvement and influence on the conduct and reporting of a trial varies. The degree of influence is difficult to assess from trial reports. We combined trials funded entirely by for-profit organizations with trials in which only drugs and placebo were provided. Sensitivity analyses showed that the significant association between funding and conclusions was present both in the group of trials having only

obtained for-profit funding in the form of drug and placebo and in the group of trials having obtained more substantial for-profit funding (data not shown).

A large proportion of trials did not report the sources of funding. It is likely that funding by for-profit organizations is underreported in trials. However, the degree of underreporting is not possible to assess. We found that about 50% of the included trials were funded solely or in part by for-profit organizations. This is in accordance with a recent review, in which the median proportion of trials receiving for-profit funding was 39% (interquartile range, 23%-64%).⁷

Conclusions reflect a trade-off between efficacy, safety, and cost-effectiveness. We did not assess the impact of cost-effectiveness on conclusions. Economic analyses are rarely included in randomized trials^{59,60} and new interventions are generally more expensive than conventional ones. Friedberg et al⁶¹ showed that studies in oncology funded by for-profit organizations were nearly 8 times less likely to reach unfavorable conclusions regarding economic assessments of experimental interventions than studies funded by nonprofit organizations.

We based our analyses on all full-paper trials that were included in the eligible meta-analyses. Trials that were only published as abstracts or letters were excluded as they very rarely contained information on funding and/or trial quality. We did not assess the studies that the authors of the Cochrane reviews had excluded from meta-analyses. The reasons for exclusion were described in all reviews. The majority of studies were excluded because they were not randomized trials. It is possible that these studies estimated a greater treatment effect because lack of randomization increases the risk of selection bias. However, it is uncertain whether the design of a study (randomized or nonrandomized) has a significant effect on the association between funding and conclusions. Our study was not designed to address this aspect.

The present study cannot show the causes or consequences of the association between for-profit funding and conclusions favoring the experimental drug. Our study was designed to assess if an association reflected the quantitative trial results. We found a significant association between conclusions and the estimated treatment effect. The likelihood of recommending the experimental drug as the treatment of choice increased significantly with increasing treatment effect (ie, decreasing *z* scores). However, this did not appear to explain the association between funding and conclusions. We found no significant difference in treatment effect between trials stratified according to funding. This is in accordance with a recent pilot study.⁶² Our findings oppose the suggestion that conclusions are more likely to be positive if funded by for-profit organizations because these trials should be more likely to reach positive results.⁸

Likely explanations for the association could be violation of the uncertainty principle, publication bias, emphasis on subgroup or secondary outcome analyses, or bias in drawing conclusions. Violation of the uncertainty principle could occur if for-profit organizations were more prone to sponsor trials that were likely to favor the experimental drug.⁵ A main objective of the pharmaceutical industry is to acquire financial gain. After having conducted exploratory randomized trials in phase 2 drug development, several confirmatory randomized phase 3 (proof of concept) trials usually are launched. Such trials may have a higher likelihood of favoring the experimental drug. Publication bias also has been suggested as a possible explanation.^{1-3,5,7,63} Concern has been raised that for-profit organizations might discontinue ongoing studies if accumulating results appear negative or if they avoid the publication of negative studies.^{1,63,64} Because of the design of the present study, we cannot refute or confirm these queries. We found no significant difference in the estimated intervention effect of the primary outcome measure between groups

of trials stratified according to funding. It is possible, that the favoring of experimental interventions in conclusions of trials funded by for-profit organizations was due to emphasis of results from surrogate outcomes,⁴⁹ secondary outcome measure analyses, or subgroup analyses.^{65,66} Finally, the association between funding and conclusions might reflect a biased interpretation of the overall trial results. This potential bias could be due to financial conflicts of interest.⁶⁷

In principle, about half of all trials should favor the control intervention.⁵ We found that trial results and conclusions rarely favored the control. This finding concurs with previous studies.^{1-4,6,57,62,64,68} The combined evidence underlines the need for an international register of all initiated randomized clinical trials. Registration would enable the public to follow the development of drugs from the beginning of phase 2 trials. Furthermore, data from unpublished randomized trials irrespective of funding source or results could be contained in an international register available to the public.^{69,70} The Consolidated Standards of Reporting Trials (CONSORT) statement⁷¹ could consider the importance of reporting of funding, as suggested by the International Committee of Medical Journal Editors.⁷² Our study suggests that editors, peer reviewers, and readers of trial reports should evaluate carefully the trial data to determine if the reported conclusions are supported by data.

Author Contributions: Study concept and design: Als-Nielsen, Gluud, Kjaergard. Acquisition of data: Als-Nielsen, Chen, Kjaergard. Analysis and interpretation of data: Als-Nielsen, Gluud, Kjaergard.

Drafting of the manuscript: Als-Nielsen.

Critical revision of the manuscript for important intellectual content: Als-Nielsen, Chen, Gluud, Kjaergard. Statistical expertise: Als-Nielsen, Kjaergard.

Obtained funding: Als-Nielsen, Gluud.

Administrative, technical, or material support: Gluud. Study supervision: Gluud.

Funding/Support: This work was funded by the Danish Centre for Evaluation and Health Technology Assessment (DACEHTA), The Danish Medical Research Council, and The Copenhagen Hospital Corporation's Medical Research Council.

Acknowledgment: We thank the authors who provided additional data on their systematic reviews or trials; Lene Theil Skovgaard for statistical advice and valuable comments on an early draft of the manuscript; Sarah Frederiksen for help with collecting the

trials; Dimitrinka Nikolova for translating trials published in Polish; and Winnie Lauersen for translating trials published in Spanish.

REFERENCES

- Davidson RA. Source of funding and outcome of clinical trials. *J Gen Intern Med.* 1986;1:155-158.
- Yaphe J, Edman R, Knishkowsky B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. *Fam Pract.* 2001;18:565-568.
- Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in BMJ. *BMJ.* 2002;325:249-252.
- Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Arch Intern Med.* 1994;154:157-163.
- Djulgovic B, Lavecic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. *Lancet.* 2000;356:635-638.
- Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA.* 2003;289:454-465.
- Lexchin J, Bero LA, Djulgovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ.* 2003;326:1167-1170.
- Jacobs A. Association between competing interests and conclusions [letter]. *BMJ.* 2002;325:1420.
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA.* 1995;273:408-412.
- Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med.* 2001;135:982-989.
- Egger M, Juni P, Bartlett C, Hohenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? empirical study. *Health Technol Assess.* 2003;7:1-76.
- Balk EM, Boris PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. *JAMA.* 2002;287:2973-2982.
- The Cochrane Database of Systematic Reviews. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
- Gilbert JP, McPeck B, Mosteller F. Statistics and ethics in surgery and anesthesia. *Science.* 1977;198:684-689.
- Altman DG. *Practical Statistics for Medical Research.* London, England: Chapman & Hall; 1991.
- Hosmer D, Lemeshow S. *Applied Logistic Regression.* New York, NY: Wiley & Sons; 1989.
- Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping cough in children [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
- Olliaro P, Mussano P. Amodiaquine for treating malaria [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
- Henry DA, Moxey AJ, Carless PA, et al. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
- French LM, Smail FM. Antibiotic regimens for endometritis after delivery [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
- Roos YB, WEM, Rinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal

subarachnoid haemorrhage [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

22. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B. Auranofin versus placebo in rheumatoid arthritis [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

23. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL. Bronchodilators for bronchiolitis [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

24. Feigin VL, Rinkel GJE, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

25. Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

26. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

27. Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

28. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

29. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

30. Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

31. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

32. Gibbs S, Harvey I, Sterling JC, Stark R. Local treatments for cutaneous warts [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

33. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

34. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

35. Wood-Baker R, Walters E.H, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

36. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

37. Garner P, Gülmezoglu AM. Prevention versus treatment for malaria in pregnant women [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

38. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R. Progestagens for endometrial cancer [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.

39. Tan BP, Hannah ME. Prostaglandins versus oxy-

- tocin for prelabour rupture of membranes at term [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
40. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
41. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001; issue 2.
42. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-634.
43. Jadad AR, Cook DJ, Jones A, et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. *JAMA*. 1998;280:278-280.
44. Jadad AR, Moher M, Browman GP, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. *BMJ*. 2000;320:537-540.
45. Streiner DL, Norman GR. *Health Measurement Scales: A Practical Guide to Their Development and Use*. 2nd ed. Oxford, England: Oxford Medical Publications; 1995.
46. The Cochrane Library. Oxford, England: Update Software; 2003; issue 2.
47. Zhang B, Schmidt B. Do we measure the right end points? a systematic review of primary outcomes in recent neonatal randomized clinical trials. *J Pediatr*. 2001;138:76-80.
48. Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Liberati A. Is proper methodology associated with the use of a clinically relevant outcome measure? the case of randomized clinical trials on medical treatment of open-angle glaucoma. *Online J Curr Clin Trials* [serial online]. 1993. Doc No. 100.
49. Gøtzsche PC, Liberati A, Torri V, Rossetti L. Beware of surrogate outcome measures. *Int J Technol Assess Health Care*. 1996;12:238-246.
50. Roberts L, Counsell C. Assessment of clinical outcomes in acute stroke trials. *Stroke*. 1998;29:986-991.
51. Duncan PW, Jorgensen HS, Wase DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. *Stroke*. 2000;31:1429-1438.
52. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. *N Engl J Med*. 1987;317:426-432.
53. Clarke M, Oxman A, ed. *Cochrane Reviewers' Handbook 4.1.6* [updated January 2003]. Oxford, England: Cochrane Library, Update Software; 2003; issue 2.
54. International Conference on Harmonisation Expert Working Group. *Code of Federal Regulations & International Conference on Harmonization Guidelines*. Philadelphia, Pa: Parexel Barnett; 1997.
55. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. *Hepatology*. 1999;30:1134-1138.
56. Huwiler-Müntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. *JAMA*. 2002;287:2801-2804.
57. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy, I: medical. *Stat Med*. 1989;8:441-454.
58. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ [authors' electronic response]. Available at: <http://bmj.com/cgi/content/full/325/7358/249>. Accessibility verified July 7, 2003.
59. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. *Med Care*. 1992;30:231-243.
60. Gluud C, Kjaergard LL. Quality of randomized clinical trials in portal hypertension and other fields of hepatology. In: de Franchis R, ed. *Portal Hypertension III: Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies*. Oxford, England: Blackwell Science; 2001:204-218.
61. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. *JAMA*. 1999;282:1453-1457.
62. Clifford T, Barrowman N, Moher D. Funding source, trial outcome and reporting quality: are they related? results of a pilot study. *BMC Health Serv Res*. 2002;2:18-23.
63. Melander H, Ahlqvist-Rastad J, Meijer G, Beer-mann B. Evidence based medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ*. 2003;326:1171-1173.
64. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet*. 1991;337:867-872.
65. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. *JAMA*. 1991;266:93-98.
66. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? *BMJ*. 2001;322:989-991.
67. Thompson DF. Understanding financial conflicts of interest. *N Engl J Med*. 1993;329:573-576.
68. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of non-steroidal antiinflammatory drugs in rheumatoid arthritis. *Control Clin Trials*. 1989;10:31-56.
69. Simes RJ. Publication bias: the case for an international registry of clinical trials. *J Clin Oncol*. 1986;4:1529-1541.
70. Horton R. Medical editors trial amnesty. *Lancet*. 1997;350:756.
71. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA*. 2001;285:1987-1991.
72. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. *JAMA*. 2001;286:1232-1234.